GERN
Biotechnology · Healthcare
Equibles does not estimate personal net worth.
The proxy statement of Geron Corp reports total compensation of $1,265,100 for Aleksandra Rizo in fiscal 2021, including a base salary of $506,374. Disclosed compensation is on record for 3 fiscal years. Aleksandra Rizo has spoken on 2 earnings calls across 1 company, most recently for Geron Corp on January 10, 2022. The companies whose calls Aleksandra Rizo spoke on are classified in the Healthcare sector.
“In 2021, our clinical focus was on advancing our two Phase 2 trials in lower-risk MDS and refractory MF. This focus will continue in 2022 as we prepare for TLR for the IMerge Phase 3 trial and complete opening sites for the IMpactMF trial.”
“As supported by our compelling Phase II data, we believe imetelstat is clearly differentiated from the currently available treatments for low-risk MDS patients, who are relapsed or refractory to ESA.”
Source not stated
Start not stated–2022-07-08
GERN
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Geron Corp (GERN) | M.D., Ph.D. Executive Vice President, Chief Medical Officer | $506,374 | $1,265,100 |
| 2020 | Geron Corp (GERN) | M.D., Ph.D. Executive Vice President, Chief Medical Officer | $491,625 | $1,134,946 |
| 2019 | Geron Corp (GERN) | M.D., Ph.D. Executive Vice President, Chief Medical Officer | $475,000 | $1,531,454 |